Chemed Corp. (CHE) PT Raised to $220.00 at Oppenheimer Holdings, Inc.
Chemed Corp. (NYSE:CHE) had its target price upped by Oppenheimer Holdings, Inc. from $200.00 to $220.00 in a research note released on Thursday morning. Oppenheimer Holdings, Inc. currently has an outperform rating on the stock. Oppenheimer Holdings also issued estimates for Chemed Corp.’s Q4 2017 earnings at $2.23 EPS, Q1 2018 earnings at $1.95 EPS, Q2 2018 earnings at $2.09 EPS, Q3 2018 earnings at $2.14 EPS and FY2018 earnings at $8.61 EPS.
A number of other equities research analysts have also recently commented on CHE. Zacks Investment Research cut shares of Chemed Corp. from a buy rating to a hold rating in a research note on Tuesday, May 2nd. BidaskClub cut shares of Chemed Corp. from a strong-buy rating to a buy rating in a research note on Thursday, June 22nd. Royal Bank Of Canada reissued a hold rating and issued a $208.00 price objective on shares of Chemed Corp. in a research note on Wednesday, July 5th. Finally, TheStreet cut shares of Chemed Corp. from a b+ rating to a c+ rating in a research note on Tuesday, July 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Chemed Corp. currently has an average rating of Buy and an average target price of $218.00.
Chemed Corp. (NYSE CHE) opened at 199.98 on Thursday. Chemed Corp. has a 52 week low of $130.05 and a 52 week high of $216.01. The firm’s 50-day moving average is $204.65 and its 200-day moving average is $189.96. The stock has a market capitalization of $3.20 billion, a P/E ratio of 49.61 and a beta of 1.15.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, beating the Zacks’ consensus estimate of $1.89 by $0.26. The firm had revenue of $415.06 million for the quarter, compared to analysts’ expectations of $407.56 million. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.80 EPS. On average, equities research analysts predict that Chemed Corp. will post $8.14 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Chemed Corp. (CHE) PT Raised to $220.00 at Oppenheimer Holdings, Inc.” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/chemed-corp-che-pt-raised-to-220-00-at-oppenheimer-holdings-inc/1463881.html.
In other Chemed Corp. news, insider Kevin J. Mcnamara sold 4,000 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $205.11, for a total value of $820,440.00. Following the transaction, the insider now directly owns 148,943 shares in the company, valued at approximately $30,549,698.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director George J. Walsh III bought 1,000 shares of Chemed Corp. stock in a transaction on Monday, June 26th. The stock was purchased at an average price of $204.56 per share, for a total transaction of $204,560.00. Following the completion of the acquisition, the director now owns 7,908 shares in the company, valued at approximately $1,617,660.48. The disclosure for this purchase can be found here. 5.32% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares during the period. Vanguard Group Inc. raised its position in Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares during the period. Neuberger Berman Group LLC raised its position in Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock worth $193,725,000 after buying an additional 23,306 shares during the period. Acadian Asset Management LLC raised its position in Chemed Corp. by 1.3% in the second quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock worth $118,454,000 after buying an additional 7,636 shares during the period. Finally, Van Berkom & Associates Inc. raised its position in Chemed Corp. by 0.5% in the first quarter. Van Berkom & Associates Inc. now owns 467,536 shares of the company’s stock worth $85,414,000 after buying an additional 2,260 shares during the period. Institutional investors own 97.75% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.